首页COH • ASX
add
科利耳
市场资讯
财务信息
损益表
收入
净收入
| (AUD) | 2024年6月info | 年同比变化 |
|---|---|---|
收入 | 5.69亿 | 8.20% |
经营支出 | 3.05亿 | 5.74% |
净收入 | 8270.00万 | 4.03% |
净利润率 | 14.55 | -3.83% |
每股收益 | — | — |
息税折旧摊销前利润 | 1.26亿 | 16.26% |
有效税率 | 26.42% | — |
资产负债表
总资产
负债总额
| (AUD) | 2024年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 5.14亿 | -7.54% |
总资产 | 27.45亿 | 6.87% |
负债总额 | 9.05亿 | 10.33% |
权益总额 | 18.40亿 | — |
发行在外的股份 | 6549.42万 | — |
市净率 | 11.23 | — |
资产回报率 | 11.42% | — |
资本回报率 | 15.04% | — |
现金流
现金净变动
| (AUD) | 2024年6月info | 年同比变化 |
|---|---|---|
净收入 | 8270.00万 | 4.03% |
来自运营的现金 | 1.16亿 | -15.22% |
投资现金 | -2895.00万 | -44.39% |
融资现金 | -7320.00万 | 26.69% |
现金净变动 | 1420.00万 | -15.98% |
自由现金流 | 8396.25万 | 23.15% |
简介
Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant.
Based in Sydney, Cochlear was formed in 1981 as a subsidiary of Nucleus with finance from the Australian government to commercialise the implants pioneered by Dr. Graeme Clark, although the company later became separate. As of 2022, the company holds 50% of the cochlear implant market, with more than 250,000 people receiving one of Cochlear's implants as of 2015.
Cochlear was named Australia's most innovative company by the Intellectual Property Research Institute of Australia in 2002 and 2003, and one of the world's most innovative companies by Forbes in 2011. Wikipedia
CEO
成立时间
1981
员工数量
5,047
